Business
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
PONTE VEDRA, Fla., April 03, 2025--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/2aaa600f622af70dd600f3f495698cd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0lHSMMhLZmLm5feE4p3hJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2aaa600f622af70dd600f3f495698cd7","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KO79sGqLFrayeCaVwObnNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2aaa600f622af70dd600f3f495698cd7","width":1200,"height":278}},"lazy":false},{"type":"text","content":"Management Available for One-to-One Meetings","length":44,"tagName":"p","attribs":{}},{"type":"text","content":"PONTE VEDRA, Fla., April 03, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.","length":465,"tagName":"p"},{"type":"text","content":"Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy.","length":284,"tagName":"p"},{"type":"text","content":"Additionally, Dr. Ferguson will attend the 13th annual CMO Summit 360° ® taking place on April 7-8, the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations.","length":261,"tagName":"p"},{"type":"text","content":"Expanding its industry and business development engagement, the Company will be at the BIO International Convention, the world’s largest biotechnology conference, from June 16-19, 2025 in Boston, MA, to meet with potential partners and collaborators to advance and enhance our lead program, tecarfarin and to build our pipeline in speci...